Payment overview · 2025
General Payments
$90,375.53
104 reported records · 10 companies
Healthcare provider profile · identity verified
Jean M Elwing, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CINCINNATI, OH · NPI 1164503355
Verified facts
What the public records show
CMS Open Payments records show Jean M Elwing, MD received $90,375.53 in general payments during 2025 across 104 reported records.
Merck Sharp & Dohme LLC accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Opsumit, Opsynvi, Remodulin, Uptravi, Winrevair.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 677 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSYNVI as an associated drug or biological on 4271 records involving 3021 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Opsynvi by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 565 claims for Uptravi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Adempas by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Adempas by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WINREVAIR as an associated drug or biological on 10378 records involving 3703 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Winrevair by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
United Therapeutics Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMODULIN as an associated drug or biological on 1683 records involving 780 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Remodulin by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30,180.84 | 33.4% | 43 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28,185.85 | 31.2% | 16 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $26,842.01 | 29.7% | 35 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $4,808.00 | 5.3% | 2 | 2025 |
| Liquidia Technologies, Inc. | Unresolved — no canonical attribution shown | $140.41 | 0.2% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $109.86 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.69 | 0.1% | 3 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $22.47 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.10 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $75,079.25 | 15 |
| Travel and Lodging | $6,990.68 | 23 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,480.00 | 1 |
| Food and Beverage | $3,746.61 | 64 |
| Education | $78.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $20,027.96 | 13 | 2025 |
Source payment records
|
|||||
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $17,585.44 | 22 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $5,967.54 | 4 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $5,865.39 | 32 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $368.21 | 4 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $261.84 | 4 | 2025 |
Source payment records
|
|||||
| Orenitram Normalized: orenitram |
Drug | United Therapeutics Corporation | $147.29 | 1 | 2025 |
Source payment records
|
|||||
| YUTREPIA Normalized: yutrepia |
Drug | Liquidia Technologies, Inc. | $140.41 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $53.69 | 3 | 2025 |
Source payment records
|
|||||
| TREPROSTINIL Normalized: treprostinil |
Drug | Sandoz Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 179 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 677 | exact normalized | Medicare Part D |
| OPSYNVI opsynvi |
2025 | Opsynvi | 2024 | 85 | exact normalized | Medicare Part D |
| Remodulin remodulin |
2025 | Remodulin | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 565 | exact normalized | Medicare Part D |
| WINREVAIR winrevair |
2025 | Winrevair | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
677 | 82 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSYNVI open payments reported associated product |
CMS Open Payments — General Payments 4271 supporting records · 3021 recipient NPIs · example record 1174164038 |
Opsynvi · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
565 | 65 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
179 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 39 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
179 | 21 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | WINREVAIR open payments reported associated product |
CMS Open Payments — General Payments 10378 supporting records · 3703 recipient NPIs · example record 1237992436 |
Winrevair · 2024 Exact normalized brand match · 1 Part D row |
128 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| United Therapeutics Corporation Exact reporting entity; no affiliate inference |
2025 | REMODULIN open payments reported associated product |
CMS Open Payments — General Payments 1683 supporting records · 780 recipient NPIs · example record 1242523648 |
Remodulin · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Opsumit | Macitentan | 677 | 82 |
| Uptravi | Selexipag | 565 | 65 |
| Tadalafil | Tadalafil | 466 | 90 |
| Famotidine | Famotidine | 323 | 110 |
| Sildenafil Citrate | Sildenafil Citrate | 323 | 87 |
| Ambrisentan | Ambrisentan | 261 | 30 |
| Spironolactone | Spironolactone | 241 | 77 |
| Omeprazole | Omeprazole | 233 | 65 |
| Torsemide | Torsemide | 224 | 61 |
| Adempas | Riociguat | 179 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 39 |
| Furosemide | Furosemide | 156 | 47 |
| Montelukast Sodium | Montelukast Sodium | 139 | 43 |
| Winrevair | Sotatercept-Csrk | 128 | 19 |
| Azelastine Hcl | Azelastine Hcl | 109 | 51 |
| Tyvaso Dpi | Treprostinil | 98 | 11 |
| Opsynvi | Macitentan/Tadalafil | 85 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 22 |
| Prednisone | Prednisone | 70 | 35 |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 16 |
| Eliquis | Apixaban | 50 | 11 |
| Potassium Chloride | Potassium Chloride | 48 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | 14 |
| Loperamide | Loperamide Hcl | 41 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 30 |
| Remodulin | Treprostinil Sodium | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Orenitram Er | Treprostinil Diolamine | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Letairis | Ambrisentan | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Ofev | Nintedanib Esylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90,375.53 · 104 records | Merck Sharp & Dohme LLC | Adempas, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OPSUMIT, OPSYNVI, Orenitram, PANZYGA, Remodulin, TREPROSTINIL, TYVASO, UPTRAVI, WINREVAIR, YUTREPIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error